Recombinant Human EPO

• Description :

  EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of Epo comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of Epo is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behavior of Epo in vivo. Non-glycosylated Epo has an extremely short biological half life. It still binds to its receptor and may even have a higher specific activity in vitro.

• Gene Name :

  EPO

• Gene Aliases :

  INN=Epoetin
  Recombinant Human Erythropoietin-Alpha (EPO)

• Gene ID :

  2056

• Accession Number :

  P01588

• Organism :

  Human

• Source :

  CHO

• Concentration :

  <1.0 EU/μg of recombinant protein as determined by the LAL method.

• Purity :

  >95% as determined by SDS-PAGE

• Solubility :

  A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

• Function :

  Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be 3.8 x 10^5 IU/mg.

• Molecular Weight :

  20

• Shipping Conditions :

  Ambient Temperature

• Storage Conditions :

  The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

• Appearance :

  Lyophilized Powder

• Formulation :

  Lyophilized from a 0.2 μm filtered solution in PBS (pH 7)

• CAS Number :

  9000-83-3